How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy

Overview

Journal Cancer Res

Specialty Oncology

Date 2020 Jun 20

PMID 32554552

Citations 25

Authors

Jinyang Li

Ben Z Stanger

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has revolutionized cancer treatment, yet most patients do not respond. While tumor antigens are needed for effective immunotherapy, a favorable tumor immune microenvironment is also critical. In this review, we discuss emerging evidence that tumor cells exploit cellular plasticity and dedifferentiation programs to avoid immune surveillance, which in turn drives metastatic dissemination and resistance to immunotherapy. A deeper understanding of these programs may provide novel opportunities to enhance the efficacy of existing immunotherapies.

Citing Articles

ITGB1/FERMT1 mechanoactivation enhances CD44 characteristic stemness in oral squamous cell carcinoma via ubiquitin-dependent CK1α degradation.

Li X, Zhao H, Jiang E, Liu P, Chen Y, Wang Y Oncogene. 2025; .

PMID: 40044983 DOI: 10.1038/s41388-025-03317-z.

Exploring thymic stromal lymphopoietin in the breast cancer microenvironment: A preliminary study.

Marcella S, Braile M, Grimaldi A, Soricelli A, Smaldone G Oncol Lett. 2025; 29(4):182.

PMID: 40007626 PMC: 11851057. DOI: 10.3892/ol.2025.14928.

Role and value of the tumor microenvironment in the progression and treatment resistance of gastric cancer (Review).

Yun H, Dong F, Wei X, Yan X, Zhang R, Zhang X Oncol Rep. 2024; 53(1).

PMID: 39611496 PMC: 11622107. DOI: 10.3892/or.2024.8847.

The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations.

Masciale V, Banchelli F, Grisendi G, Samarelli A, Raineri G, Rossi T J Biol Chem. 2024; 300(12):107994.

PMID: 39547513 PMC: 11714729. DOI: 10.1016/j.jbc.2024.107994.

The immunological and prognostic significance of the diabetes mellitus-related gene WFS1 in endometrial cancer.

Li W, Ke D, Xu Y, Wang Y, Wang Q, Tan J Front Immunol. 2024; 15:1464421.

PMID: 39478865 PMC: 11521820. DOI: 10.3389/fimmu.2024.1464421.

References

Gordeeva O . Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer therapy. Semin Cancer Biol. 2018; 53:75-89. DOI: 10.1016/j.semcancer.2018.08.006. View

Mak M, Tong P, Diao L, Cardnell R, Gibbons D, William W . A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res. 2015; 22(3):609-20. PMC: 4737991. DOI: 10.1158/1078-0432.CCR-15-0876. View

Friedmann-Morvinski D, Verma I . Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep. 2014; 15(3):244-53. PMC: 3989690. DOI: 10.1002/embr.201338254. View

Casey S, Tong L, Li Y, Do R, Walz S, Fitzgerald K . MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016; 352(6282):227-31. PMC: 4940030. DOI: 10.1126/science.aac9935. View

Gibbs Z, Whitehurst A . Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors. Trends Cancer. 2018; 4(10):701-712. PMC: 6366644. DOI: 10.1016/j.trecan.2018.08.005. View

Pylayeva-Gupta Y, Lee K, Hajdu C, Miller G, Bar-Sagi D . Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell. 2012; 21(6):836-47. PMC: 3721510. DOI: 10.1016/j.ccr.2012.04.024. View

Pommier A, Anaparthy N, Memos N, Kelley Z, Gouronnec A, Yan R . Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 2018; 360(6394). PMC: 6547380. DOI: 10.1126/science.aao4908. View

Agudo J, Park E, Rose S, Alibo E, Sweeney R, Dhainaut M . Quiescent Tissue Stem Cells Evade Immune Surveillance. Immunity. 2018; 48(2):271-285.e5. PMC: 5824652. DOI: 10.1016/j.immuni.2018.02.001. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

10.

Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay R, Luoma A . A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018; 359(6377):770-775. PMC: 5953516. DOI: 10.1126/science.aao1710. View

11.

Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D . MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun. 2015; 6:8755. PMC: 4659938. DOI: 10.1038/ncomms9755. View

12.

Dorand R, Nthale J, Myers J, Barkauskas D, Avril S, Chirieleison S . Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science. 2016; 353(6297):399-403. PMC: 5051664. DOI: 10.1126/science.aae0477. View

13.

Xiong H . Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol. 2004; 54 Suppl 1:S69-77. DOI: 10.1007/s00280-004-0890-2. View

14.

Burr M, Sparbier C, Chan K, Chan Y, Kersbergen A, Lam E . An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell. 2019; 36(4):385-401.e8. PMC: 6876280. DOI: 10.1016/j.ccell.2019.08.008. View

15.

Liu W, Tian M, Yang L, Lin Y, Jin L, Ding Z . PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. Oncotarget. 2014; 6(2):846-61. PMC: 4359260. DOI: 10.18632/oncotarget.2749. View

16.

Lou Y, Diao L, Parra Cuentas E, Denning W, Chen L, Fan Y . Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res. 2016; 22(14):3630-42. PMC: 4947453. DOI: 10.1158/1078-0432.CCR-15-1434. View

17.

Vinay D, Ryan E, Pawelec G, Talib W, Stagg J, Elkord E . Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015; 35 Suppl:S185-S198. DOI: 10.1016/j.semcancer.2015.03.004. View

18.

Li F, Huang Q, Luster T, Hu H, Zhang H, Ng W . Epigenetic CRISPR Screen Identifies as an Immunotherapeutic Target in -Mutant Lung Adenocarcinoma. Cancer Discov. 2019; 10(2):270-287. PMC: 7007372. DOI: 10.1158/2159-8290.CD-19-0780. View

19.

Kalbasi A, Ribas A . Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2019; 20(1):25-39. PMC: 8499690. DOI: 10.1038/s41577-019-0218-4. View

20.

Wagers A, Weissman I . Plasticity of adult stem cells. Cell. 2004; 116(5):639-48. DOI: 10.1016/s0092-8674(04)00208-9. View